Alnylam Pharmaceuticals

Hingham,  MA 
United States
  • Booth: 2401

Headquartered in Cambridge, MA, Alnylam is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases. Alnylam’s first U.S. FDA approved RNAi therapeutic is ONPATTRO™ (patisiran), with four investigational medicines in late-stage clinical development.

For Technical Support with this webpage, please contact support.